Clinical Trial Update: A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial of IMV102 for relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IMV102

Snippet

Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd | Conditions: Relapsed/Refractory Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING